Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
MATINAS BIOPHARMA HOLDINGS INC (MTNB)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.16-2.52%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MTNB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain stable executive leadership during CFO transition | A supporting condition in MATINAS BIOPHARMA HOLDINGS INC's published investment case. The stated target is No further executive departures disrupting operations. | Under Pressure | Additional key executive departures or leadership disruptions | 1 executive departure vs 0 allowed July 2026 events show CEO transition and director resignation, confirming leadership disruption. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, high-risk business rather than an established compounder, with earnings quality classified as loss-making and management execution viewed as volatile. The current long-term thesis is on watch: recent financial performance is neutral but below its industry cohort, and confidence in the assessment is low.
The valuation signal says MTNB is cheap versus peers, but confidence in that comparison is low and the business is loss-making. The evidence does not specify what operating expectations are already reflected in the valuation, so the expectations gap is unclear; no fragility gates have fired.
Near term, ongoing losses and equity financing needs remain central: recent raises brought in $575,000 and about $2.6 million for working capital and corporate purposes. The company has a plan accepted to regain NYSE American compliance by October 2, 2027, but compliance has not yet been achieved after stockholders’ equity fell from $4.83 million at the end of 2025 to $1.8 million by mid-2026. The sector backdrop has improved, but the evidence flags elevated near-term miss risk and does not establish a clear improvement in company fundamentals.
Over the next 1 to 3 years, a key swing factor is whether MTNB can regain listing compliance while managing its capital needs and ongoing losses. The sector tailwind may persist if bellwethers VRTX, REGN, and MRNA keep beating earnings and guiding higher, but could fade if they miss or guide lower. Weaker jobs data could also raise recession concerns for cyclical names, though the evidence does not show how directly that applies to MTNB.
The multi-year view remains uncertain and high risk, with listing compliance, financing, and company-level progress as the main tests; sector strength is a secondary support, not proof of a business turnaround. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce net losses and improve operating income |
| Matinas is cutting losses and improving operating income. |
| Intact |
| Operating income falls below -$1.94M |
Operating income: $-1.555M FY2026-Q2; GAAP. Published target: Operating income better than -$1.94M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-1,555,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve NYSE listing compliance issues | Management works to fix NYSE compliance problems. | Under Pressure | Any new NYSE noncompliance notice or delisting | 2 noncompliance notices vs 0 target NYSE issued noncompliance notices in June and September 2026 citing failure to meet continued listing standards. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.50 → $-37.50 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-25 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-26 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-27 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-28 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-29 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-30 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-07-31 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-01 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-02 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-03 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-04 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-05 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-06 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-07 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-08 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-09 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-10 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-12 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-13 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-14 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-15 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-16 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-17 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-18 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-19 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-20 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-21 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-22 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-23 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-24 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-25 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-26 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-27 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-28 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-29 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-30 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-08-31 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-01 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-02 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-03 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-04 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-05 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-06 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-07 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-08 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-09 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-10 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-11 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-12 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-13 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-14 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-15 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-16 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-17 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-18 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-19 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-20 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-21 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-22 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-23 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-24 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-25 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-26 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-27 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-28 | $-2.50 | $45,202,000 | 1 / 1 |
| 2026-09-29 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-09-30 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-01 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-02 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-03 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-04 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-05 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-06 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-07 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-08 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-09 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-10 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-11 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-12 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-13 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-14 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-15 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-16 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-17 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-18 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-19 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-20 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-21 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-22 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-23 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-24 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-25 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-26 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-27 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-28 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-29 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-30 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-10-31 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-11-01 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-11-02 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-11-03 | $-37.50 | $45,202,000 | 1 / 1 |
| 2026-11-04 | $-37.50 | $45,202,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.